President Donald Trump signed an executive order on Saturday directing federal agencies to expedite reviews of certain psychedelic drugs, including ibogaine, for mental health applications such as PTSD and opioid addiction. The signing occurred in the Oval Office, with Health Secretary Robert F. Kennedy Jr.'s prior pledges noted, and ibogaine confirmed as a Schedule I substance. While veteran advocates support its potential, specific claims about clinical trials and additional officials remain unverified.